Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament based on rosmarinic acid and application thereof in treating Parkinson's disease

A technology of rosmarinic acid and drugs, applied in the field of rosmarinic acid-based drugs and its application in the treatment of Parkinson's disease, can solve the problems of adverse reactions, limited application and promotion, and achieve the reduction of active oxygen species The effect of reducing the decrease in mitochondrial membrane potential and reducing the survival rate of dopaminergic cells

Inactive Publication Date: 2010-07-14
QINGDAO UNIV
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to overcome the shortcomings of the prior art. For traditional anti-PD drugs generally have some adverse reactions, which seriously limit its application and promotion. It aims to provide a rosmarinic acid-based drug and its Application in the treatment of Parkinson's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament based on rosmarinic acid and application thereof in treating Parkinson's disease
  • Medicament based on rosmarinic acid and application thereof in treating Parkinson's disease
  • Medicament based on rosmarinic acid and application thereof in treating Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1: The neuroprotective effect of the rosmarinic acid-sodium citrate drug of the present invention on MES23.5 dopaminergic cells

[0017] 1. Experimental materials

[0018] (1) cells

[0019] MES23.5 dopaminergic cells were donated by Professor Weidong Le of Baylor College of Medicine in Houston, USA. Place it at 37 °C, 5% CO 2 cultured in an incubator.

[0020] (2) Drugs and reagents

[0021] Rosmarinic acid was provided by Professor Li Ronggui from the Department of Biology, Qingdao University School of Medicine. -3 mol / L storage. Diluted with culture medium to the required concentration of 10 during the experiment -6 ~10 -13 mol / L. Sodium citrate is a product of Sinopharm Chemical Reagent Co., Ltd. During the experiment, it was diluted with culture medium to the required concentration of 10 -2 mol / L. Dimethyl sulfoxide (DMSO), 2,7-dihydrodichlorofluorescein sodium diacetate (H 2 DCF-DA), 6-OHDA, MPP + , Rhodamine 123, 3-(4,5-dimethylthiazole-2)-2,5...

Embodiment 2

[0079] Embodiment 2: In vitro toxicity test of rosmarinic acid-sodium citrate

[0080] 1. Experimental materials

[0081] (1) Drugs and reagents

[0082] Lactate dehydrogenase (LDH) detection kit is a product of Nanjing Jiancheng Bioengineering Institute.

[0083] (2) Instruments

[0084] Microplate reader: R-T-2100C, Shenzhen Redu Company.

[0085] 2. Experimental method

[0086] Take MES23.5 dopaminergic cells in the logarithmic growth phase, pipette to make a single cell suspension, centrifuge, and dilute to 2×10 with complete medium 5 cells / ml cell suspension, inoculated in 96-well plate with 200 μl per well, placed at 37°C, 5% CO 2 cultured in an incubator. After the cell confluency reaches 70-80%, it is replaced with serum-free medium and drug treatment. The concentration of rosmarinic acid was added to 10 -13 , 10 -12 , 10 -11 , 10 -10 , 10 -9 mol / L and 10 -2 mol / L sodium citrate, after incubating MES23.5 dopaminergic cells for 24 hours, the negative contro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicament based on rosmarinic acid and application thereof in treating Parkinson's disease. According to the formula of the medicament, the medicament comprises rosmarinic acid and sodium citrate with the molar concentration thereof being 1:104 to 1:1011. The medicament achieving the effect of neuroprotection in MES23.5 dopaminergic cells can obviously relieve the reduction in the survival rate of the MES23.5 cells caused by the induction of neurotoxin, i.e., 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenylpyridine cations, obviously relieve the reduction in the mitochondrial membrane potential of the cells caused by the induction of neurotoxin, i.e., 1-methyl-4-phenylpyridine cations and the generation of ROS (reactive oxygen species) substances and obviously improve the morphologic changes of nuclei caused by the induction of neurotoxin, i.e., 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenylpyridine cations, thereby achieving the effects of neuropretection, oxidation resistance and apoptosis resistance. The medicament of the invention having low toxicity and side effect has significant application prospect and actual value for the development into a novel anti-Parkinsonism natural medicament.

Description

Technical field: [0001] The present invention relates to a medicine based on rosmarinic acid and its application in the treatment of Parkinson's disease, in particular to rosmarinic acid-sodium citrate pharmaceutical formula and its effect on dopaminergic neurons in the treatment of Parkinson's disease Neuroprotective applications. It belongs to the field of medical technology. Background technique: [0002] Parkinson's disease (PD) is the most common neurodegenerative disease, and its pathological feature is the selective death of dopaminergic neurons in the substantia nigra area of ​​the brain. The incidence of PD in my country has increased by at least 20 times in the past 20 years, which will not only affect the quality of life of patients, but also cause a huge mental and economic burden to families and society. More seriously, there is no mature and effective drug or method that can prevent or reverse the development of PD. Therefore, people have been devoting thems...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K31/194A61P25/16
Inventor 谢俊霞姜宏李荣贵宋宁杜婷婷
Owner QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com